Country for PR: Hong Kong
Contributor: PR Newswire Asia (Hong Kong)
Wednesday, September 25 2019 - 15:09
AsiaNet
Helsinn and Mundipharma China Pharmaceutical jointly announce NMPA's approval of the oral formulation of Akynzeo(R) in China
LUGANO, Switzerland and BEIJING, Sept. 25, 2019 /PRNewswire-AsiaNet/ --

Helsinn, a Swiss pharmaceutical group focused on building quality cancer care 
products, and Mundipharma China Pharmaceutical, the market leader in pain 
management, today jointly announce that the National Medical Products 
Administration (NMPA) has approved the oral formulation of Akynzeo(R) for the 
treatment of chemotherapy-induced nausea and vomiting (CINV) in China.

Logo - https://photos.prnasia.com/prnh/20190925/2591427-1

Under the terms of the agreement, Mundipharma China Pharmaceutical has 
exclusive marketing, promotion and sale rights for the oral formulation of 
Akynzeo(R) in China. Helsinn will be responsible for supplying the drug to 
Mundipharma and co-detailing the product in Shanghai while retaining all 
international development rights, including clinical development activities.

Riccardo Braglia, Helsinn Group Vice Chairman and CEO commented: "Lack of 
control of CINV is a problem despite the availability of several antiemetics. 
We are pleased that Akynzeo(R) that targets two CINV critical pathways in a 
single dose will help patients and their families also in China

"We are also very pleased to be working in partnership with Mundipharma 
Pharmaceutical. Their expert knowledge and network in China will be invaluable 
as we begin to market Akynzeo(R) in this strategically important region."

Peter Wang, CEO of Mundipharma Pharmaceutical Greater China commented: "Today's 
announcement will be welcomed by Chinese cancer patients, who are undergoing 
chemotherapy while having to fight against CINV, as well as caregivers. It is 
also an important extension of Mundipharma China's portfolio. We look forward 
to continuing to partner with Helsinn to bring more high-quality cancer 
supportive care products to millions of Chinese cancer patients in the near 
future, in line with our vision of 'Bring more to life."

About Akynzeo(R) in China

Akynzeo(R) capsule (300 mg netupitant/0.5 mg palonosetron) was approved on Aug 
2th, 2019 in China and is indicated in adults for the prevention of acute and 
delayed nausea and vomiting associated with highly emetogenic cancer 
chemotherapy, and prevention of acute and delayed nausea and vomiting 
associated with moderately emetogenic cancer chemotherapy.

About the Helsinn Group

Helsinn is a privately owned pharmaceutical group with an extensive portfolio 
of marketed cancer care products and a robust drug development pipeline. Since 
1976, Helsinn has been improving the everyday lives of patients, guided by core 
family values of respect, integrity and quality. The Group works across 
pharmaceuticals, biotechnology, medical devices and nutritional supplements and 
has expertise in research, development, manufacture and the commercialization 
of therapeutic and supportive care products for cancer, pain and inflammation 
and gastroenterology. In 2016, Helsinn created the Helsinn Investment Fund to 
support early-stage investment opportunities in areas of unmet patient need. 
The company is headquartered in Lugano, Switzerland, with operating 
subsidiaries in Switzerland, Ireland, the U.S., Monaco and China, as well as a 
product presence in approximately 190 countries globally.

To learn more about Helsinn Group please visit www.helsinn.com and follow us on 
Twitter[https://twitter.com/HelsinnGroup], 
LinkedIn[https://www.linkedin.com/company/101863/] and 
Vimeo[https://vimeo.com/helsinn]

About Mundipharma China Pharmaceutical

Mundipharma China Pharmaceutical was established in the year of 1993 and has 
been dedicated to the organic growth of the pain segment in China for decades. 
"Bring More to Life" is our aspiration; caring for lives and serving the 
society is our social responsibilities. Innovation, patient-centric, and 
entrepreneurship are in our DNAs.

In the future, Mundipharma China will continue to explore in pain management 
field and expand its business into new fields, including CINV, transplantation 
immunology, oncology, respiratory, and etc. We'll make unremitting efforts to 
providing innovative products and fulfilling our social responsibilities, 
ultimately to realize our vision of "Bring More to Life".

For more information, please refer to: http://www.mundipharma.com.cn 

SOURCE Mundipharma China Pharmaceutical

Image Attachments Links:

   Link: http://asianetnews.net/view-attachment?attach-id=346020

   Caption: Logo

Translations

Japanese

Vietnamese